Brief: Valbiotis/Phase II HEART Study: TOTUM•070 Effective Against Hypercholesterolemia

Valbiotis SA

13/06/2022 17:37

June 13 (Reuters) - Valbiotis SA  ALVAL.PA :
    * VALBIOTIS ANNOUNCES THE MAJOR SUCCESS OF THE PHASE II
HEART
CLINICAL STUDY: THE PATENTED PLANT-BASED ACTIVE SUBSTANCE
TOTUM•070 PROVES ITS EFFICACY AGAINST HYPERCHOLESTEROLEMIA, A
CARDIOVASCULAR RISK FACTOR
    * STUDY CONFIRMED SAFETY AND VERY GOOD TOLERANCE OF
TOTUM•070
    * VALBIOTIS SETS THE OBJECTIVE OF COMMERCIALIZATION BASED ON
THESE
PHASE II RESULTS, NO LATER THAN THE FIRST HALF OF 2024, AND IS
INTENSIFYING ITS DISCUSSIONS WITH MAJOR HEALTH AND NUTRITION
PLAYERS

Source text for Eikon:  ID:nBw7PJ9Ffa 
Further company coverage:  ALVAL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))